{"preliminary_commentary":{"by_channel":{"x_thread":4,"bluesky_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"SHR-A2102","nct_id":"NCT05701709","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=shr-a2102-nct05701709. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"SHR-A2102","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-08-31","type":"ESTIMATED"},"conditions":["Advanced Solid Tumors"],"enrollment":{"count":395,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"SHR-A2102","otherNames":[],"type":"DRUG"}],"last_update":"2025-07-22","lead_sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","official_title":"An Open-Label, Single-Arm, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of SHR-A2102 in Patients With Advanced Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2025-08-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of participants with adverse events","timeFrame":"24 months"},{"measure":"Maximum tolerated dose (MTD)","timeFrame":"12 weeks"},{"measure":"Recommended Phase 2 dose (RP2D)","timeFrame":"24 months"},{"measure":"Dose Limiting Toxicity (DLT)","timeFrame":"3 weeks"}],"references":[{"citation":"Zhong R, Hong H, Yan M, Wang Q, Zhang Y, Lan Q, Luo Y, Zhang L, Xu H, Guo S, Guo W, Ma J, Zhang L, Wu L, Liu Z, He W, Sun Y, Chen K, Huang J, Han G, Nian W, Zhang M, Ren S, Qiao R, Li X, Yu M, Hu J, Huang Y, Song L, Shi W, Zhong H. SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial. Lancet Oncol. 2026 Sep;27(9):1146-1157. doi: 10.1016/S1470-2045(26)00238-X.","pmid":"42636836","type":"DERIVED"}],"start_date":{"date":"2023-04-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT05701709"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/shr-a2102-nct05701709"}